As of today, Juul Labs has reached settlements with plaintiffs in the federal multidistrict litigation (MDL) and related “JUUL Labs Product Cases” (JCCP) that have been consolidated in the United States District Court for the Northern District of California.
These settlements represent a major step toward strengthening Juul Labs’ operations and securing the company’s path forward to fulfill its mission to transition adult smokers away from combustible cigarettes while combating underage use.
The global resolution covers more than 5,000 cases brought by approximately 10,000 plaintiffs against Juul Labs and its officers and directors. These cases in the MDL and JCCP, and subject to the resolution, come from the following groups: personal injury, consumer class action, government entity, and Native American tribes. As part of the settlement and court process, Juul Labs cannot disclose the settlement amount at this time, but has secured an equity investment to fund the resolution.
Over the past year, Juul Labs also has settled with 37 states and territories and we remain in ongoing discussions with other key stakeholders to resolve the remaining litigation.
As the company announced in November, Juul Labs has taken a series of steps to stabilize its business operations and address past legal issues. With both new investments in the company’s mission and a resolution like the one achieved today, Juul Labs is charting a path forward to continue to advance tobacco harm reduction through science and technology, for over 31 million adult smokers in the U.S. and over 1 billion adult smokers worldwide.
October 2, 2024
On September 26th, Juul Labs’ Chairman & Chief Executive Officer, K.C. Crosthwaite, delivered the keynote address at the 2024 Global Tobacco & Nicotine Forum,…
July 29, 2024
Juul Labs announced today the settlement with a group of noteholders that confirms the conversion of the convertible notes to equity, and provides an…
June 6, 2024
Today, the FDA rescinded its June 2022 Marketing Denial Orders (MDOs) for the JUUL System and placed our applications back into scientific review. We appreciate the FDA’s decision and now look forward to re-engaging with the agency on a science- and evidence-based process to pursue a marketing authorization for JUUL products.